These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14648718)

  • 1. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers.
    Neuhausen S; Dunning A; Steele L; Yakumo K; Hoffman M; Szabo C; Tee L; Baines C; Pharoah P; Goldgar D; Easton D
    Int J Cancer; 2004 Jan; 108(3):477-8. PubMed ID: 14648718
    [No Abstract]   [Full Text] [Related]  

  • 2. CHEK2*1100delC and male breast cancer risk in Israel.
    Ohayon T; Gal I; Baruch RG; Szabo C; Friedman E
    Int J Cancer; 2004 Jan; 108(3):479-80. PubMed ID: 14648719
    [No Abstract]   [Full Text] [Related]  

  • 3. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2:1100delC and female breast cancer in the United States.
    Mateus Pereira LH; Sigurdson AJ; Doody MM; Pineda MA; Alexander BH; Greene MH; Struewing JP
    Int J Cancer; 2004 Nov; 112(3):541-3. PubMed ID: 15382084
    [No Abstract]   [Full Text] [Related]  

  • 6. CHEK2 1100delC and male breast cancer in the Netherlands.
    Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
    Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
    Hallamies S; Pelttari LM; Poikonen-Saksela P; Jekunen A; Jukkola-Vuorinen A; Auvinen P; Blomqvist C; Aittomäki K; Mattson J; Nevanlinna H
    BMC Cancer; 2017 Sep; 17(1):620. PubMed ID: 28874143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of familial male breast cancer for germline mutations in CHEK2.
    Sodha N; Wilson C; Bullock SL; Phillimore H; Houlston RS; Eeles RA
    Cancer Lett; 2004 Nov; 215(2):187-9. PubMed ID: 15488637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
    Choi DH; Cho DY; Lee MH; Park HS; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2008 Dec; 112(3):569-73. PubMed ID: 18175216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
    Kleibl Z; Novotny J; Bezdickova D; Malik R; Kleiblova P; Foretova L; Petruzelka L; Ilencikova D; Cinek P; Pohlreich P
    Breast Cancer Res Treat; 2005 Mar; 90(2):165-7. PubMed ID: 15803363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay.
    Manguoğlu E; Güran S; Yamaç D; Simşek M; Akdeniz S; Colak T; Gülkesen H; Lüleci G
    Cancer Invest; 2011 Jan; 29(1):73-7. PubMed ID: 20919953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.